News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,540 Results
Type
Article (13793)
Company Profile (101)
Press Release (251646)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88054)
Career Advice (465)
Deals (15343)
Drug Delivery (67)
Drug Development (36605)
Employer Resources (49)
FDA (6292)
Job Trends (6200)
News (150233)
Policy (14036)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23222)
ALS (36)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (38)
Approvals (6328)
Artificial intelligence (106)
Autoimmune disease (9)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (20)
Brain cancer (16)
Breast cancer (78)
Cancer (600)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (22)
Cell therapy (86)
Cervical cancer (4)
Clinical research (30908)
Collaboration (333)
Compensation (152)
Complete response letters (17)
COVID-19 (757)
CRISPR (20)
C-suite (121)
Cystic fibrosis (37)
Data (622)
Denatured (15)
Depression (9)
Diabetes (78)
Diagnostics (1317)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (60)
Drug pricing (64)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32108)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37451)
Executive appointments (377)
FDA (6706)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (209)
Gene editing (38)
Generative AI (9)
Gene therapy (100)
GLP-1 (346)
Government (1296)
Grass and pollen (2)
Guidances (16)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (792)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (47)
Interviews (59)
IPO (5875)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (11)
Layoffs (180)
Leadership (3)
Legal (3433)
Liver cancer (19)
Lung cancer (80)
Lymphoma (53)
Machine learning (1)
Management (16)
Manufacturing (150)
MASH (32)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9672)
Metabolic disorders (256)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (6)
Neuroscience (573)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (699)
Now hiring (7)
Obesity (146)
Opinion (119)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (46)
Partnered (7)
Patents (112)
Patient recruitment (28)
Peanut (10)
People (28924)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8043)
Phase II (13075)
Phase III (11736)
Pipeline (437)
Policy (68)
Postmarket research (1401)
Preclinical (3214)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (166)
Real estate (2637)
Recruiting (17)
Regulatory (10106)
Reports (14)
Research institute (565)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (36)
Series A (36)
Series B (12)
Service/supplier (3)
Sickle cell disease (32)
Southern California (714)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (31)
Tariffs (20)
The Weekly (30)
United States (7100)
Vaccines (150)
Venture capitalists (13)
Weight loss (99)
Women's health (8)
Worklife (3)
Date
Today (40)
Last 7 days (172)
Last 30 days (873)
Last 365 days (11860)
2025 (3395)
2024 (12502)
2023 (14246)
2022 (19556)
2021 (20069)
2020 (19033)
2019 (14885)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20109)
Australia (2611)
California (1692)
Canada (899)
China (235)
Colorado (65)
Connecticut (67)
Delaware (54)
Europe (39417)
Florida (321)
Georgia (37)
Idaho (9)
Illinois (192)
India (16)
Indiana (132)
Iowa (1)
Japan (90)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (252)
Massachusetts (1462)
Michigan (30)
Minnesota (93)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (758)
New Mexico (7)
New York (497)
North Carolina (386)
North Dakota (2)
Northern California (699)
Ohio (49)
Oklahoma (4)
Oregon (16)
Pennsylvania (434)
Puerto Rico (8)
Rhode Island (8)
South America (502)
South Carolina (2)
Southern California (714)
Tennessee (34)
Texas (225)
Utah (33)
Virginia (72)
Washington D.C. (31)
Washington State (116)
Wisconsin (15)
265,540 Results for "bellicum pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Bellicum Weighs Options After Serious Safety Concerns Halt Only Trials
Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns.
March 15, 2023
·
1 min read
·
Hayleigh Evans
Lone Star Bio
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
Bellicum Pharmaceuticals, Inc. today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally.
October 4, 2022
·
1 min read
Drug Development
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients.
March 14, 2023
·
1 min read
Drug Development
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
Bellicum Pharmaceuticals, Inc. today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T ® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
January 19, 2023
·
1 min read
Lone Star Bio
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 31, 2023
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options.
January 31, 2023
·
1 min read
Business
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the third quarter 2022 and provided an operational update.
November 10, 2022
·
8 min read
Drug Development
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually.
February 16, 2023
·
6 min read
Lone Star Bio
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid).
September 1, 2022
·
1 min read
Business
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the second quarter 2022 and provided an operational update.
August 11, 2022
·
6 min read
Lone Star Bio
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 31, 2022
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options.
October 31, 2022
·
1 min read
1 of 26,554
Next
